Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

HYALURONIDASE-OCSQ\OCRELIZUMAB for Relapsing multiple sclerosis: Side Effects & Safety Data

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

There are 32 adverse event reports in the FDA FAERS database where HYALURONIDASE-OCSQ\OCRELIZUMAB was used for Relapsing multiple sclerosis.

Most Reported Side Effects for HYALURONIDASE-OCSQ\OCRELIZUMAB

Side Effect Reports % Deaths Hosp.
Injection site erythema 23 13.5% 0 2
Off label use 21 12.3% 0 1
Injection site pain 20 11.7% 0 2
Contusion 17 9.9% 0 1
Fatigue 17 9.9% 0 0
No adverse event 13 7.6% 0 0
Pain 13 7.6% 0 0
Erythema 12 7.0% 0 0
Injection site reaction 12 7.0% 0 0
Headache 10 5.9% 0 0
Injection site swelling 10 5.9% 0 2
Rash 10 5.9% 0 0
Swelling 8 4.7% 0 0
Pain in extremity 7 4.1% 0 0
Multiple sclerosis relapse 6 3.5% 0 1

Other Indications for HYALURONIDASE-OCSQ\OCRELIZUMAB

Multiple sclerosis (65) Product used for unknown indication (41) Relapsing-remitting multiple sclerosis (20) Primary progressive multiple sclerosis (14)

Other Drugs Used for Relapsing multiple sclerosis

OCRELIZUMAB (6,883) OFATUMUMAB (3,705) FINGOLIMOD (851) GLATIRAMER (375) ALEMTUZUMAB (350) SIPONIMOD (194) INTERFERON BETA-1A (192) NATALIZUMAB (140) RITUXIMAB (136) OZANIMOD (127)

Related Pages

HYALURONIDASE-OCSQ\OCRELIZUMAB Full Profile All Relapsing multiple sclerosis Drugs HYALURONIDASE-OCSQ\OCRELIZUMAB Demographics HYALURONIDASE-OCSQ\OCRELIZUMAB Timeline